Purpose: We prospectively evaluated the diagnostic performance of prostate specific membrane antigen targeted 18 F-DCFPyL positron emission tomography/ computerized tomography in the preoperative staging of men at high risk for harboring metastatic prostate cancer despite a negative conventional staging evaluation. Materials and Methods: Men with clinically localized high or very high risk prostate cancer were imaged with 18 F-DCFPyL positron emission tomography/ computerized tomography before undergoing radical prostatectomy with standardized pelvic lymph node dissection. The scans were interpreted by 2 blinded nuclear medicine readers and assessed for interreader variability as well as diagnostic accuracy for pelvic lymph node staging. Surgical pathology served as the reference standard to which 18 F-DCFPyL scan findings were compared.
65.3e98.6). Analysis at the level of individual nodal packets resulted in 66.7% sensitivity (95% CI 29.9e92.5) and 92.7% specificity (95% CI 80.1e98.5). Three men (12%) had evidence of M1a disease.
Conclusions:
18 F-DCFPyL positron emission tomography/computerized tomography allowed for accurate detection of prostate cancer sites in men believed to have clinically localized disease based on conventional imaging. Our results support the need for a larger study to more precisely define the diagnostic accuracy of this novel molecular imaging test.
Key Words: prostatic neoplasms; 2-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido) pentanedioic acid; positron-emission tomography; tomography, X-ray computed; diagnosis DEFINITIVE local treatment with radical prostatectomy or radiation therapy remains the standard of care in men with intermediate or high risk PCa. Prior to undergoing treatment patients at risk for harboring metastatic PCa should undergo a staging evaluation using a combination of 99m Tc-methylene diphosphonate bone scan as well as pelvic imaging with CT or MRI. Current guidelines recommend a risk adapted approach to the use of staging imaging in men newly diagnosed with PCa, taking into account pretreatment serum PSA level, clinical T stage and biopsy Gleason sum. 1e3 However, despite appropriate staging imaging use up to 30% of men with high risk PCa will be found to have clinically occult lymph node metastases at radical prostatectomy. 4, 5 Additionally, a significant proportion of men will have persistently elevated PSA or biochemical recurrence following surgery. 6e9 In the absence of positive surgical margins these treatment failures can be attributed to sites of extraprostatic disease that escaped detection by conventional imaging at the time of initial cancer staging.
In an effort to improve the accuracy of currently available modalities of PCa imaging there has been growing interest in PET. 10 A number of novel PET radiotracers have been explored for this purpose. 11, 12 Most promising among them is the class of radiotracers targeting PSMA, a type II glycoprotein that is over expressed in more than 95% of prostate tumors. 13, 14 To date, the majority of work on PSMA targeted PET imaging has been performed using the urea based small molecule 68 Ga-PSMA-11, also known as 68 Ga-PSMA-HBED-CC. However, there are several limitations related to using 68 Ga as a PET radionuclide, including the inability to produce large batch quantities of radiotracer and distribution of the agent to distant imaging centers.
These issues can be addressed using alternative 18 F labeled radiotracers. 15, 16 Indeed, multiple fluorinated compounds targeting PSMA have been developed. 17, 18 Furthest along in clinical development is the 18 F-DCFPyL radiotracer, which was first described by Chen et al. 19 This radiotracer has been examined in several studies in the context of imaging biochemically recurrent or metastatic PCa. 20e22 We report the results of a prospective, phase II, single center study evaluating the diagnostic performance of 18 F-DCFPyL PET/CT in the preoperative staging of men at high risk for harboring metastatic PCa despite a negative staging evaluation with conventional imaging.
PATIENTS AND METHODS
This study was approved by The Johns Hopkins Medical Institutions institutional review board (NA_00092956 /J1418) as an extension of a previously completed, first in human study evaluating the 18 F-DCFPyL radiotracer (ClinicalTrials.gov Identifier NCT02151760). 20 All study procedures were done in accordance with the Declaration of Helsinki and the International Conference on Harmonisation of Good Clinical Practice.
Men with clinically localized high or very high risk PCa as defined by the NCCNÒ 3 were eligible for this study. Pre-enrollment clinical stage was determined with 99m Tc-methlyene diphosphonate bone scan as well as CT or MRI of the pelvis. In accordance with recommendations from the PCWG3 (Prostate Cancer Clinical Trials Working Group 3) 23 lymph nodes measuring greater than 15 mm in axial diameter were considered pathologically enlarged. Patients with such findings on cross-sectional imaging were deemed ineligible for this study.
Upon signing informed consent, patients underwent 18 F-DCFPyL PET/CT as previously described. 20 In brief, 1 hour after intravenous administration of approximately 9 mCi 18 F-DCFPyL radiotracer, a PET/CT scan was acquired from the mid thigh to the vertex of the skull. Of note, patients were asked to void prior to imaging to decrease bladder activity. Radiotracer for this study was synthesized locally at our center using the method previously described by Ravert et al. 24 One to 7 days after PET/CT radical prostatectomy with bilateral pelvic lymph node dissection was performed by 1 of 5 expert urological oncologists. The overall surgical technique (ie robotic vs open) was determined at the discretion of the treating surgeon. Regardless of surgical approach, all lymph node dissections were performed using a standardized anatomical template (supplementary figure, http://jurology.com/), which resulted in removal of 2 lymph node packets per patient (ie 1 per side of the pelvis). At the completion of the study 2 genitourinary pathologists (AMDM and IV) blinded to imaging results collaboratively reviewed the surgical specimens. Two blinded nuclear medicine readers (MSJ and LBS) independently read the 18 F-DCFPyL PET/CT scans in separate random orders. These reads were assessed for concordance of the number of lesions located in the prostate gland, overall N stage, N stage on each side of the pelvis and M stage. All cases with discordant N or M stage between the 2 reads were then reconciled by collaborative rereview.
Using surgical pathology as the reference standard the parameters calculated with respect to lymph node staging were sensitivity, specificity, and positive and negative predictive values. This analysis was performed at the level of the 25 patients overall as well as the 50 individual lymph node packets. Calculations were performed with MedCalcÒ, version 17.1.
RESULTS
A total of 28 patients were enrolled in this study between March 2015 and September 2016, and no adverse events were encountered during the study. Complete analyzable data were available on 25 enrolled patients (89.3%). One patient was excluded from analysis after he was mistakenly enrolled with metastatic disease found on conventional imaging. Another patient was excluded from study after we learned that staging imaging had been done 8 months preoperatively, leaving clinical stage at prostatectomy open to question. Finally, a third patient was excluded because pelvic lymph node dissection could not be safely performed due to a large iliac artery aneurysm. Table 1 shows detailed characteristics of the 25 patients included in analysis. Median patient age was 61 years (range 49 to 75) and median PSA was 9.3 ng/ml (range 3.6 to 125.5) at the time of study enrollment. On biopsy before prostatectomy Gleason score was 4 þ 5 ¼ 9 or 5 þ 4 ¼ 9 in 13 study subjects (52%). Additionally, 14 men (56%) had palpable disease on digital rectal examination (ie cT2a or greater) and 8 (32%) met the definition of having very high risk PCa.
Following radical prostatectomy 18 patients (72%) were found to have Gleason 4 þ 5 ¼ 9 or 5 þ 4 ¼ 9 PCa (table 1). In terms of primary tumor staging 13 cases (52%) were pT3a and 7 (28%) were pT3b. A median of 13 lymph nodes (range 5 to 45) were removed at surgery. Seven men (28%) were found to have 1 or more positive lymph nodes. Notably, 2 of these patients (29%) had bilateral lymph node involvement, resulting in a total of 9 positive lymph packets. A median of 3 disease involved lymph nodes (range 1 to 7) were found in each positive nodal packet. Positive lymph nodes were typically small with a median diameter of 3 mm (range 1 to 12).
With respect to 18 F-DCFPyL PET/CT findings 1 reader detected 32 discrete intraprostatic lesions among the 25 imaged patients. These lesions had a median SUV max of 7.0 (range 3.0 to 40.2). The second reader detected 29 intraprostatic lesions with a median SUV max of 6.6 (range 3.3 to 37.8). The 2 readers identified the same number of lesions in 22 cases (88%) and all cases had at least 1 intraprostatic lesion in common between the 2 reads. Additionally, the readers assigned the same N stage to 46 of the 50 individual lymph node packets (92%) and to 22 of the 25 cases overall (88%). Finally, 24 patients (96%) were assigned the same clinical M stage. Figures 1 and 2 show representative images of patients believed to have localized and distant disease, respectively, based on 18 F-DCFPyL PET/CT. After reconciling the relatively few discordant reads, 7 patients (28%) were found to have 1 or more sites of focal radiotracer in the pelvis consistent 
DISCUSSION
In this study we prospectively evaluated the diagnostic performance of 18 F-DCFPyL PET/CT to preoperatively stage high risk PCa in men believed to have clinically localized disease based on conventional imaging. This represents the first study to evaluate this novel imaging test in the setting of preoperative PCa staging. 18 F-DCFPyL PET/CT correctly identified 5 of 7 cases (71.4%) with otherwise clinically occult positive lymph nodes while over staging only 2 cases (8%). To place the observed sensitivity value in context, 50% of disease involved lymph nodes were less than 3 mm. Perhaps more importantly, 18 F-DCFPyL PET/CT identified putative sites of distant metastases in 3 men (12%). Finally, this novel imaging test identified discrete foci of abnormal radiotracer uptake in the prostate gland of all imaged patients. Given the normal biodistribution and the low background uptake of the radiotracer, these sites likely corresponded to areas of PCa. This finding suggests that this imaging test can be used to aid in the topographic mapping of cancer in the prostate and in fact other PSMA targeted radiotracers have shown promise for this purpose. 10, 13, 14 As with any new imaging test, it is important to understand its performance characteristics with respect to interreader variability. In this study we observed a high degree of concordance between our 2 readers in terms of detecting local and distant sites of disease. We believe that the readers were able to achieve this high level of concordance between reads due to the low blood pool and the background activity of the 18 F-DCFPyL radiotracer. Given this, the lesions, even those with low SUV values, had a high degree of conspicuity, allowing for high confidence calls by the readers.
However, an area of particular difficulty for readers was the assessment of pelvic lymph nodes located near the ureters. Like many agents used for molecular imaging, 18 F-FCFPyL is excreted in urine, making focal uptake difficult at times to discern from activity in the ureters. In our study 2 of the 3 false-positive radiotracer uptake sites (66.7%) were confirmed to be located in the ureters upon further review by a third highly experienced reader (SPR).
We suspect that with additional experience the specificity of this imaging test will improve as readers develop a framework for discerning ureteral activity. In fact, recent data on 68 Ga-PSMA-11 PET/ CT showed that increasing reader experience positively correlated with interreader agreement and presumably with accuracy to determine clinical stage. 25 The specificity of 18 F-DCFPyL PET/CT may also be improved through concurrent use of pelvic MRI, multiple imaging time points and/or administration of diuretics.
We are not alone in our observations regarding the diagnostic potential of PSMA targeted PET in the preoperative setting. A review of the literature revealed 4 studies that evaluated 68 Ga-PSMA-11 PET/CT for lymph node staging prior to radical prostatectomy. 26e29 Together these studies include data on 210 men, of whom 35.2% had pN1 disease. Meta-analysis of these studies demonstrated similar sensitivity between the 68 Ga-PSMA-11 and 18 F-DCFPyL radiotracers for preoperative lymph node staging (Supplementary Methods, and supplementary tables 1 and 2, http://jurology.com/). More specifically 61.6% sensitivity (95% CI 44.2e77.8) was observed for 68 Ga-PSMA-11 PET/CT to determine overall pN1 stage. However, the 68 Ga-PSMA-11 radiotracer had a slightly higher observed specificity of 97.6% (95% CI 89.7e100). In an analysis of individual lymph node packets sensitivity and specificity were found to be 61.4% (95% CI 39.4e81.4) and 97.8% (95% CI 93.9e100), respectively. The results of this meta-analysis suggest that PET/CT with 18 F-DCFPyL offers diagnostic performance similar to that of 68 Ga-PSMA-11. This observation strengthens our confidence in the findings of our relatively small study both of these radiotracers are urea based small molecules that bind to the catalytic domain of the PSMA protein. 30 Figure 2. Representative images of patient with suspected regional and distant lymph node metastases (N1 and M1a) detected on preoperative 18 F-DCFPyL PET/CT. Note multiple sites of focal radiotracer uptake (red arrows, SUV max values greater than 3.5). At radical prostatectomy Bilateral pelvic lymph node metastases were found at radical prostatectomy. A, maximal intensity projection. B and C, axial fused PET/CT. Our study is not without limitations, foremost being the small sample size of only 25 patients. Another limitation is the lack of prostate whole mounts to confirm that radiotracer uptake in the prostate glands localized to sites of cancer. Along these lines, we lacked histological proof in the 3 cases reclassified with M1a disease.
Despite these limitations, a considerable strength of our study is its prospective design, which is in contrast to the existing literature on PSMA targeted imaging which mostly includes retrospective studies. 13, 14 An additional strength is our use of surgical pathology as the reference standard in the analysis of diagnostic accuracy for lymph node staging.
CONCLUSIONS
We provide the first prospective evaluation of PSMA targeted PET/CT using the 18 F-DCFPyL radiotracer in the preoperative staging of men with clinically localized PCa. This novel imaging test identified sites of radiotracer uptake in the prostate gland of all imaged patients and allowed for the accurate detection of otherwise occult lymph node metastases. Moreover, a subset of men were identified with evidence of occult distant metastatic disease. A large confirmatory multicenter trial is currently under way to more definitively determine the diagnostic performance of this test for imaging local and distant sites of PCa (ClinicalTrials.gov identifier NCT02981368).
